HEALTHCARE & DRUG PRICING: THE MIDDLEMAN NOBODY VOTED FOR
Everyone budgets for the grocery bill. Fewer people know why the same prescription costs $9 at one pharmacy and $340 at another, or why "insurance" doesn't mean "affordable." That gap isn't random — it's a designed system, and it's a kitchen-table issue whether or not you've ever thought about it in political terms.
The middleman nobody talks about
Most people assume drug prices are set by pharmaceutical companies, with insurance picking up the rest. There's a third player in between: the Pharmacy Benefit Manager (PBM). PBMs negotiate which drugs get covered, set pricing, and take a cut at nearly every step — and just three companies (CVS Caremark, Express Scripts/Cigna, and Optum Rx/UnitedHealth) process about 80% of all U.S. prescription claims. That's not a competitive market. That's three companies effectively setting the terms for the entire country.
How the price gets inflated before you ever see it
Here's the mechanic insurance companies don't explain: PBMs often push manufacturers to set a high list price, then negotiate a large rebate back to themselves. Example, drawn from Senate testimony: a drug's list price gets set at $600, with a 50% rebate plus 10% in fees flowing back to the PBM.
If you're uninsured, you pay the full $600. If you're insured but haven't met your deductible, you still pay the full $600 — and the PBM still collects its rebate on that sale. High deductibles work in the PBM's favor either way: they keep collecting rebates while you pay list price, and they benefit even more if you can't afford the deductible at all, because then the plan never pays out anything.
Why your local pharmacy might be closing
PBMs frequently under-reimburse independent pharmacies until they either close or get absorbed into the PBM's own "captive" pharmacy network. That matters beyond convenience — the pharmacist relationship (catching dangerous drug interactions, answering questions face to face) disappears when independents do.
Two competing fixes — and where they actually land
Fix the middlemen, keep private insurance. Require real price transparency. Separate the entity that decides which drugs are covered from the entity collecting rebates on those drugs. Base what patients owe on the actual negotiated price, not the inflated list price. This approach has bipartisan appeal because it's framed as "anti-monopoly," not "anti-insurance" — but Congress has held roughly a dozen hearings on PBM practices since 2018 with the same pattern every time: testimony, public outrage, no legislative follow-through.
Move to universal coverage. Remove profit-seeking private insurance from the equation entirely — through single-payer, a public option, or a heavily regulated multi-payer model like Germany's or Switzerland's. Every other wealthy nation spends less per person while covering their entire population: the U.S. spent an estimated $14,885 per person on healthcare in 2024, more than double the average of comparable wealthy countries, while ranking at or below average on most health outcomes, including life expectancy. The tradeoff is transition cost, political difficulty, and honest questions about funding.
Worth noting: even universal-coverage countries haven't eliminated the "middleman" question — they've just changed who the middleman answers to. Which is the real thread connecting both approaches.
America already tried the nonprofit model
People picture "nonprofit healthcare" as something that happens somewhere else. It happened here first. Blue Cross and Blue Shield plans were founded in the 1930s as not-for-profit organizations — everyone paid the same rate regardless of age or health status, and by law, in exchange for tax breaks, BCBS plans were required to cover the people other insurers wouldn't touch.
In 1994, the Blue Cross and Blue Shield Association voted to let its nonprofit members convert to for-profit corporations. The conversions spread fast across the country. One Wisconsin conversion alone generated a $618 million payout to two medical schools — value that had built up inside the nonprofit structure and had to be spent on public benefit once the plan went for-profit. That single number says a lot about what "nonprofit" had actually been protecting.
Nonprofit healthcare didn't disappear — it's just no longer the default. Roughly 58% of U.S. community hospitals are still nonprofit, and Kaiser Permanente, covering over 13 million people, still operates as a not-for-profit health plan.
What happened when we left it
This has actually been studied directly. A multi-state analysis of BCBS conversions found that both the newly for-profit insurer and its competitors raised premiums after conversion, specifically in markets where the converting plan had real market share — evidence that removing the nonprofit anchor let the whole local market drift upward, not just one company. The same study found a side effect: Medicaid enrollment rose in those markets afterward, consistent with families losing affordable private coverage and shifting onto public coverage instead.
In fairness, this isn't unanimous. An earlier, broader government-commissioned review of 12 communities found the evidence on conversions was mixed — no clear negative or positive effect on consumers. And one study found conversions modestly increased the insured rate, since for-profit plans had more incentive to court customers the nonprofit had previously been required to cover at a loss. Nonprofit status isn't an automatic fix, either — testimony before Congress in 2025 noted that many nonprofit hospitals are under real financial strain despite the tax exemption.
The honest version: removing the profit incentive changes what an organization is optimizing for. That's the same structural feature that shows up in Switzerland's and Germany's systems, where insurers are nonprofit or tightly bound to a public-benefit mandate rather than free to maximize returns. It's not a guarantee. It's a documented lever.
Check it yourself
Peterson-KFF Health System Tracker — U.S. vs. peer-country healthcare spending and outcomes.
Drug Channels Institute — PBM market share and industry data.
Senate Special Committee on Aging — hearing records and testimony on drug pricing.
The Commonwealth Fund — international health system comparisons.
KFF (Kaiser Family Foundation) — nonpartisan healthcare policy research.
Pull the primary sources before you repeat a number in a conversation. That's the whole point of this page.
The assignment here: this isn't an abstract federal debate. State legislatures regulate insurance markets, decide Medicaid expansion, and set the rules PBMs operate under locally. Know where your state representatives stand on any of it before you assume "healthcare policy" is something that only happens in Washington.